OnKure Therapeutics Stock (NASDAQ:OKUR)

Ownership Financials Chart

Previous Close

$2.83

52W Range

$1.70 - $20.00

50D Avg

$2.62

200D Avg

$9.05

Market Cap

$38.50M

Avg Vol (3M)

$148.01K

Beta

0.42

Div Yield

-

OKUR Company Profile

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

46

IPO Date

-

Website

OKUR Performance

OKUR Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-54.39M	$-36.93M	$-29.77M
Net Income	$-52.67M	$-35.31M	$-29.51M
EBITDA	$-51.71M	$-34.75M	$-29.38M
Basic EPS	-	$-2.65	$-2.21
Diluted EPS	-	$-2.65	$-2.21

Fiscal year ends in Dec 24 | Currency in USD